4,501 Shares in Eli Lilly and Company $LLY Bought by Advisory Solutions Group LLC

Key Points

• Advisory Solutions Group LLC bought 4,501 Eli Lilly shares worth approximately $5.4 million in the second quarter, making Lilly its 11th-largest holding. Institutional investors collectively own 82.53% of the company.
• Lilly reported strong quarterly results, with EPS of $8.38 beating estimates of $6.40 and revenue of $22.97 billion rising 47.7% year over year. Analysts maintain a “Moderate Buy” consensus and an average price target of $1,292.18.
• The company declared a quarterly dividend of $1.73 per share, equivalent to an annualized $6.92 and a 0.6% yield, while insiders sold 13,500 shares worth roughly $16 million over the past three months.

Advisory Solutions Group LLC purchased a new stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 4,501 shares of the company's stock, valued at approximately $5,398,000. Eli Lilly and Company comprises about 1.8% of Advisory Solutions Group LLC's investment portfolio, making the stock its 11th biggest holding.

Several other institutional investors have also recently made changes to their positions in the business. Rose Capital Advisors LLC bought a new position in Eli Lilly and Company during the 2nd quarter valued at about $525,000. NBH Bank bought a new stake in Eli Lilly and Company in the second quarter worth about $4,668,000. AlphaGrep UK Ltd lifted its stake in Eli Lilly and Company by 23.1% in the second quarter. AlphaGrep UK Ltd now owns 710 shares of the company's stock worth $852,000 after purchasing an additional 133 shares during the last quarter. William John Sempolinski purchased a new position in shares of Eli Lilly and Company during the second quarter valued at approximately $431,000. Finally, MW Advisory LLC purchased a new position in shares of Eli Lilly and Company during the second quarter valued at approximately $2,988,000. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Performance

LLY stock opened at $1,123.60 on Wednesday. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. The business has a 50-day moving average price of $1,188.61 and a 200 day moving average price of $1,071.38. The company has a market capitalization of $1.06 trillion, a P/E ratio of 37.70, a PEG ratio of 1.42 and a beta of 0.50. Eli Lilly and Company has a 1-year low of $712.05 and a 1-year high of $1,292.65.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $1.98. The company had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. Eli Lilly and Company's revenue was up 47.7% compared to the same quarter last year. During the same period last year, the company posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, equities research analysts forecast that Eli Lilly and Company will post 36.35 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be paid a $1.73 dividend. The ex-dividend date is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company's dividend payout ratio (DPR) is 23.22%.

Insider Buying and Selling

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the company's stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the transaction, the executive vice president owned 11,875 shares in the company, valued at approximately $14,131,250. This represents a 29.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the sale, the chief accounting officer owned 1,526 shares of the company's stock, valued at $1,808,325.26. The trade was a 56.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,500 shares of company stock worth $15,958,170 in the last three months. Corporate insiders own 0.14% of the company's stock.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The FDA’s approval of Mounjaro to reduce the risk of heart attack or stroke in certain adults with type 2 diabetes could expand the drug’s addressable market and support Lilly’s next phase of growth. Could Mounjaro’s New Heart Benefit Unlock the Next Growth Phase for Lilly?
• Positive Sentiment: Analyst sentiment remains favorable, with Lilly’s average brokerage recommendation signaling optimism about its growth outlook, although such ratings can be biased toward positive recommendations. Wall Street Bulls Look Optimistic About Lilly
• Positive Sentiment: Lilly is expanding its neuroscience pipeline through internal development and acquisitions, offering potential long-term growth beyond its diabetes and obesity franchise. Lilly Builds Neuroscience into a New Long-Term Growth Driver
• Positive Sentiment: Recent acquisitions could strengthen Lilly’s pipeline and diversify its future revenue base, though investors are assessing whether the deals will justify their cost. Eli Lilly Has Been on an Acquisition Spree
• Neutral Sentiment: Lilly’s strong GLP-1 growth remains the central investment thesis, but investors are also focused on increasing competition and the eventual impact of patent expirations for Mounjaro, Zepbound and related products. Lilly’s Acquisition Strategy and GLP-1 Competition
• Negative Sentiment: Novartis’ failure in a closely watched cardiovascular trial for an Lp(a)-lowering cholesterol drug pressured the broader drug class and raised concerns about clinical and commercial risk for companies pursuing similar opportunities, including Lilly. Eli Lilly Stock Falls on Novartis Cholesterol Drug Setback
• Negative Sentiment: The stock faced broader healthcare-sector selling and a technical breakdown, which intensified the pullback despite Lilly’s favorable long-term fundamentals. Why Is Eli Lilly Stock Falling Tuesday?
• Negative Sentiment: Novo Nordisk’s positive pediatric semaglutide study highlights continued competitive progress in obesity treatment, potentially increasing pressure on Lilly’s GLP-1 franchise. Novo Nordisk’s Semaglutide Meets Goal in Pediatric Obesity Study

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on LLY shares. Bank of America increased their price target on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a "buy" rating in a report on Friday, July 10th. Royal Bank Of Canada increased their target price on Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 8th. Wells Fargo & Company lifted their target price on Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the stock an "overweight" rating in a research report on Thursday, August 6th. Cantor Fitzgerald boosted their target price on shares of Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the company an "overweight" rating in a research note on Thursday, August 6th. Finally, Wolfe Research restated an "outperform" rating and issued a $1,350.00 price target on shares of Eli Lilly and Company in a report on Thursday, May 21st. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $1,292.18.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its portfolio includes treatments for diabetes and obesity, oncology, immunology, neuroscience, cardiovascular disease and other areas of significant unmet medical need.

The company's products include Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, and insulin products such as Humalog. Lilly also markets Verzenio for certain breast cancers and Kisunla for the treatment of early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.